Clinical and prognostic differences between ALK-negative anaplastic large cell lymphoma and peripheral T cell lymphoma, not otherwise specified: a single institution experience

详细信息    查看全文

• 作者：Xiu-Wen Deng ; Xi-Mei Zhang ; Wei-Hu Wang ; Shu-Lian Wang ; Jing Jin…
• 刊名：Annals of Hematology
• 出版年：2016
• 出版时间：August 2016
• 年：2016
• 卷：95
• 期：8
• 页码：1271-1280
• 全文大小：1,028 KB
• 刊物类别：Medicine
• 刊物主题：Medicine & Public Health
  Hematology
  Oncology
  
• 出版者：Springer Berlin / Heidelberg
• ISSN：1432-0584
• 卷排序：95

文摘

Clinical differences between anaplastic lymphoma kinase (ALK)-negative anaplastic large-cell lymphoma (ALK− ALCL) and peripheral T cell lymphoma, not otherwise specified (PTCL-NOS), remain unclear. The aim of this study was to compare the clinical and prognostic features of these two lymphoma types. We retrospectively analyzed 167 patients with ALK− ALCL (n = 48) and PTCL-NOS (n = 119). Compared with ALK− ALCL patients, PTCL-NOS patients exhibited distinct differences in clinical features with a propensity for more advanced stages, frequent extranodal involvement, and a poor performance status, leading to a higher risk group according to the International Prognostic Index or Prognostic Index for PTCL-NOS. Patients with ALK− ALCL were associated with a higher complete response rate (47.9 vs. 31.0 %; P = 0.041) after initial chemotherapy than patients with PTCL-NOS. The prognosis was significantly different between two subtypes, with a 5-year overall survival (OS) rate of 57.9 % for ALK− ALCL and 23.9 % for PTCL-NOS (P = 0.002). The subgroup analysis showed significant differences in OS and progression-free survival between the two subtypes in early-stage diseases, but not in advanced-stage diseases. We conclude that patients with ALK− ALCL showed favorable clinical features, higher chemosensitivity, and a superior outcome than those with PTCL-NOS.KeywordsALK-negative anaplastic large-cell lymphomaPeripheral T cell lymphoma, not otherwise specifiedPrognosisChemotherapyRadiotherapy